Pharma Sales Force Sizing: How Many Reps Do You Actually Need?

The short answer

Pharma sales force sizing comes down to one sum: the number of calls your target prescribers and accounts need in a year, divided by the number of calls one rep can actually deliver in a year, then adjusted for vacancies and ramp-up. Get the call universe right and the rest is arithmetic. Get it wrong and no amount of territory design will rescue the number.

Most sizing mistakes are not maths mistakes. They are data mistakes: a target list padded with prescribers who will never write the brand, call frequencies copied from a primary care benchmark onto a specialty launch, or a capacity figure that assumes reps spend every working day in front of doctors. This guide walks through how to build the number properly, with a worked example for a specialty launch, the data sources that feed it, and the cases where the right answer is a smaller field force or none at all.

It is written for commercial and sales operations leaders at small and mid-sized pharma and biotech companies who need a defensible headcount for a board, a launch plan or a budget cycle, without a six-month consulting project.

Reference points worth knowing

Three ways to size a pharma sales force

There are three standard methods, and a sound plan uses at least two of them so each one checks the other. ZS co-founders Andris Zoltners and Prabhakant Sinha, with Sally Lorimer, cover sizing, structure and territory alignment in depth in Sales Force Design for Strategic Advantage (Palgrave Macmillan, 2004).

For a launch the workload buildup is the backbone, because there is no sales history to fit a response curve to. For an established brand the response model is the more honest test, because it asks whether the marginal rep earns back their cost rather than whether there is enough work to keep them busy. Axtria argues in its commentary on why pharma brand directors over-resource their direct sales effort that incentives and risk aversion push headcount above what profit would justify. A territory can always be filled with activity; the question is whether that activity is profitable.

How to run a workload buildup, step by step

Worked example: how many reps does a specialty launch need?

The figures below are assumptions for illustration, not benchmarks. They show how the maths works for a specialty brand where the treating universe is a few thousand prescribers rather than the tens of thousands a primary care launch would chase.

Capacity per rep. Assume 220 working days, of which 40 go to training, national and regional meetings, admin and leave. That leaves 180 field days. At 4.5 completed calls a field day, one rep delivers 810 calls a year.

Raw headcount. 20,400 calls divided by 810 calls gives 25.2 reps.

Vacancy and ramp. Assume 15 percent of reps leave in a year and each departure costs four months of capacity while the role is refilled and the new hire gets up to speed. That loses about 5 percent of capacity (0.15 x 4/12). Dividing 25.2 by 0.95 gives 26.5, so plan for 27 territories.

Managers. At one first-line manager for every eight to ten reps, that adds three district managers.

Cost check. Using the BLS May 2023 mean wage of $120,370 as a floor, 27 reps cost about $3.25 million a year in wages alone, before bonus, benefits, fleet, devices, samples, meetings and management. Divide your fully loaded figure by 27 and compare it with the expected net revenue each territory will produce in years one and two. If a third of the territories cannot cover their own cost, the honest answer is fewer territories with larger geographies, or an inside sales team covering segment C.

Now change one assumption. If the brand lead decides segment A needs 24 calls a year instead of 16, calls needed rise by 3,600 and the force grows by about five reps. That is why the frequency assumption, not the formula, is the decision that deserves the most argument. For how those territories are then drawn, see our guide to territory alignment and call planning in pharma.

What data do you need to size a sales force?

The universe and the segmentation are where most of the work goes. A mid-sized company can build a credible first version from a mix of public and licensed data:

• NPPES (the CMS NPI registry). Free, and the backbone of the prescriber list: NPI, name, practice address and taxonomy code. It tells you who exists and where, not who treats your patients.
• CMS Medicare Part D Prescribers by Provider and Drug. Published annually on data.cms.gov, it shows Part D claims by prescriber and drug. It is useful for ranking prescribers in a therapy class, but it covers Medicare only, is released well over a year after the claims it describes, and excludes any prescriber and drug row with fewer than 11 claims. For a rare disease brand, many of your best targets may simply not appear.
• Syndicated prescription and claims data. Licensed sources such as IQVIA or Symphony Health give all-payer prescriber-level volume and diagnosis-based patient counts. If you are choosing between them, our Symphony Health vs IQVIA comparison covers the trade-offs.
• HCP reference data. A clean master of prescribers and their affiliations so the same doctor is not counted twice under two addresses. Veeva OpenData and IQVIA OneKey are the two main US sources.
• Your CRM history. If you already have a field force, actual calls per field day, access restrictions and no-see rates from Veeva or Salesforce beat any benchmark. Our Veeva CRM data integration work usually starts by pulling exactly these numbers.

The output of this stage is a single table: one row per target, with segment, call frequency, geography and access status. Every later decision, including territory alignment and incentive goals, reads from it, so it is worth building once in a proper data model rather than in a spreadsheet that gets rebuilt every year.

Own reps, contract sales or a hybrid model?

Own field force

You hire, train and keep the reps. You control the message, the culture and the data, and you build relationships that compound over the life of the brand. You also carry fixed cost, recruitment time and the risk of being over-sized if the launch is slow.

Contract sales (CSO)

A contract sales organisation supplies a trained team on a fixed-term contract. It lets you test a size, cover a launch window or add a temporary indication without permanent headcount. Make sure the contract gives you call-level data in your own CRM and a clear path to convert reps to employees.

Hybrid and inside sales

Field reps cover segment A and key accounts; an inside or virtual team covers segments B and C by phone, video and approved email. This often removes the territories that failed the cost check in the worked example while keeping those prescribers covered.

Account-led

Where formulary committees, health-system pharmacies or infusion centres decide, a smaller team of key account managers may matter more than prescriber reps. Size it from the account list and the number of decision makers per account, not from prescriber counts.

Common pharma sales force sizing mistakes

• Counting every prescriber

  A universe built from total prescribing rather than indication potential inflates segment C and adds territories that will never pay back.

• Borrowed call frequencies

  Primary care frequencies applied to a specialty brand, or the other way round, swing the headcount by double-digit percentages.

• Capacity with no downtime

  Assuming every working day is a field day overstates capacity and quietly under-sizes the team, which then misses its call plan.

• Ignoring vacancies

  Territories are never all filled. A plan with no vacancy or ramp allowance is short from the day it is approved.

• Sizing after alignment

  Drawing territories first and then counting reps bakes in today's map. Size first, align second.

• Never revisiting the number

  A launch force sized on year-one assumptions should be re-run once real uptake, access and call data arrive, usually within the first year.

When not to build a field force

Test the size before you commit to it

A sizing model is a forecast, so treat it like one. Before hiring the full number, compare a pilot set of territories with a matched set that receives less coverage, and measure new-to-brand prescriptions, new patient starts and account activation over a defined period. Even a simple test-and-control read beats arguing about benchmarks.

That only works if the data is in place on day one: a prescriber master, demand data at prescriber level, CRM activity, and the territory roster, joined in one place so you can see coverage, reach and frequency against the plan every week. This is the same foundation our pharma launch analytics work builds, and the same data that later drives fair pharma incentive compensation goals. Greenwolf's founder came up through pharma commercial operations consulting at ZS, and our pharma commercial analytics consulting team builds the call universe, the sizing model and the dashboards that show whether the field force you approved is the one you needed.

Questions about pharma sales force sizing